Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAY1225 DDI Study with Warfarin, Atorvastatin, Metformin, and Digoxin
NCT07362030Phase 1Active, not recruiting
- Sponsor
- Raynovent Biotech
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of RAY1225 in obesity, sponsored by Raynovent Biotech. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Started Apr 2025; status: active, not recruiting.
02
Drugs
RAY1225
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07362030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362030.